EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
09/07/2021 - 07:00 AM
WATERTOWN, Mass, Sept. 07, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced that EyePoint Pharmaceuticals’ senior management team will present at the following four upcoming conferences:
Ophthalmology Futures Euro Forums 2021 Virtual Retina Forum Forum: Corporate Presentation and Panel featuring Jay Duker, M.D., Chief Strategic Scientific Officer of EyePoint Pharmaceuticals Date: Wednesday, September 8, 2021 Time: 7:50AM-3:30PM Eastern Time H.C. Wainwright 23 rd Annual Global Investor Conference Forum: Corporate Presentation Date: Monday, September 13, 2021 Time: 7:00AM Eastern Time Cantor Fitzgerald Virtual Global Healthcare Conference Forum: Corporate Presentation Date: Wednesday, September 29, 2021 Time: 8:40-9:10 AM Eastern Time Benzinga Healthcare Small Cap Conference Forum: Corporate Presentation Date: Thursday, September 30, 2021 Time: 11:55AM-12:15PM Eastern Time The H.C. Wainwright 23rd Annual Global Investor Conference, Cantor Fitzgerald Virtual Global Healthcare Conference and Benzinga Healthcare Small Cap Conference presentations will be recorded, and a webcast and subsequent archived replay of each recorded corporate presentation may be accessed via the Investors section of the Company website at www.eyepointpharma.com .
About EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT) is a pharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary Durasert® technology for sustained intraocular drug delivery including EYP-1901, a potential twice-yearly sustained delivery intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. The Company has two commercial products: YUTIQ® , for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU® , for the treatment of postoperative inflammation following ocular surgery. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts. To learn more about the Company, please visit www.eyepointpharma.com and connect on Twitter and LinkedIn.
Investors:
Christina Tartaglia Stern IR Direct: 212-698-8700christina.tartaglia@sternir.com
Media Contact
Amy Phillips Green Room Communications Direct: 412-327-9499aphillips@greenroompr.com
EyePoint Pharmaceuticals Inc
EYPT Rankings
#1302 Ranked by Stock Gains
EYPT Stock Data
Industry
Analytical Laboratory Instrument Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Major, Manufacturing, Analytical Laboratory Instrument Manufacturing
About EYPT
psivida corp., (nasdaq: psdv) (asx: pva) headquartered in watertown, ma, develops tiny, sustained release, drug delivery products designed to deliver drugs at a controlled and steady rate for months or years. psivida is currently focused on treatment of chronic diseases of the back of the eye utilizing its core technology systems, durasert™ and biosilicon™. the injectable, sustained release micro-insert iluvien® for the treatment of chronic diabetic macula edema (dme), licensed to alimera sciences, inc., has received marketing authorization in austria, france, germany, portugal, the u.k. spain, and italy. iluvien for dme has recently been approved in the us. psivida plans to institute pivotal phase iii clinical trials for the treatment of posterior uveitis with the same micro-insert as iluvien for dme. an investigator-sponsored clinical trial is ongoing for an injectable, bioerodible micro-insert to treat glaucoma and ocular hypertension. psivida's two fda-approved products, retisert®